Clinical usefulness of serum and immunohistochemical markers in patients with stage Ia and Ic ovarian cancer

Muramatsu, Toshiya; Mukai, Masaya; Sato, Shinkichi; Tajima, Takayuki; Nagase, Eri; Ikeda, Masae; Goya, Kenichi; Shida, Masako; Hirasawa, Takeshi; Murakami, Masaru; Shinozuka, Takao

doi:10.3892/or.14.4.861

Cited by 7 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Høgdall et al showed that a shorter disease-specific survival for patients with 30% or higher CEA expression in the tumour tissue and the highest CEA expression compared with no expression was found to be an independent prognostic factor for mucinous ovarian cancer in Danish patients [ 28 ]. In a preoperative comparison of serum tumor markers, CA 125 and CA 19.9 levels were significantly higher in IC stages than those in IA stages [ 29 ]. CA 125 levels in our study were higher in stage IB-IIIC, but there was no statistical significance.…”

Section: Discussionmentioning

confidence: 99%

Parameters of Blood Count and Tumor Markers in Patients with Borderline Ovarian Tumors: A Retrospective Analysis and Relation to Staging

et al. 2012

View full text Add to dashboard Cite

The aim of this paper was to evaluate the parameters of blood count and tumor markers in borderline ovarian tumors. We evaluated 21 patients who had confirmed histopathologic diagnosis of borderline ovarian tumor. We recorded age, parity, tumor type, stage of cancer, serum levels of tumor markers (CA-125, CA-15.3, CA-19.9, CEA, AFP), and the parameters of blood count, fasting glucose, disease-free survival and overall. The patients were divided into two groups, stage IA (n = 13) and stage IB-IIIC (n = 8). The unpaired t-test and Fisher's exact test were used, with P values of less than 0.05 being considered to indicate statistical significance. Levels of red blood cells, hematocrit, and hemoglobin were significantly higher in stage IA when compared with stage IB-IIIC (P < 0.05). The levels of tumor marker CEA had a tendency to be higher in the group stage IB-IIIC (0.08). Abnormal levels of CEA and CA-19.9 were found more frequently in stages IB-IIIC. Therefore, parameters of blood count, CEA, and CA-19.9 should be targeted for further research in identifying prognostic factors in borderline tumors.

show abstract

Section: Discussionmentioning

confidence: 99%

Parameters of Blood Count and Tumor Markers in Patients with Borderline Ovarian Tumors: A Retrospective Analysis and Relation to Staging

et al. 2012

View full text Add to dashboard Cite

show abstract

“…Thus, ONCs may serve as a useful clinical indicator of the risk of hematogenous recurrence/metastasis of colorectal cancer to the liver and lungs, but not as an indicator of recurrence/metastasis for patients with gastric cancer, particularly in the case of peritoneal dissemination. Because it was reported that ONCs are detected in stage Ic, but not stage Ia, ovarian cancer positive for tumor cells on perioperative peritoneal cytology (36), it can be inferred that gastric cancer metastasizes by releasing tumor cells directly into the peritoneal cavity from sites of serosal exposure rather than via lymph flow. It is also possible that there may be organ-specific forms of tumor dissemination.…”

Section: Discussionmentioning

confidence: 99%

Prospective study on the recurrence/metastasis of stage II/III colorectal cancer and gastric cancer associated with occult neoplastic cells in lymph node sinuses: Three-year interim results

Mukai

Tajima²,

Sato³

et al. 2006

Oncol Rep

Self Cite

View full text Add to dashboard Cite

This study was designed to prospectively examine whether the presence of occult neoplastic cells (ONCs) in lymph nodes or positive high-risk (HR) criteria were related to the survival of patients with stage II/III colorectal cancer or gastric cancer. The 3-year relapse-free survival (3Y-RFS) rate was calculated for 79 patients who were registered during a 2-year period. The 3Y-RFS rate was 80.5% in patients without ONCs (n=54) and 84.3% in patients with ONCs (n=25; p=0.9089). Among patients who had stage II/III colorectal cancer, it was 89.0% (n=47) and 76.2% (n=15), respectively (p=0.4131). For patients with stage III colorectal cancer alone, it was 80.8% (n=24) and 62.5% (n=9), respectively (p=0.4006). The 3Y-RFS rate was respectively 88.1% and 77.6% for the HR patients (n=31) and low-risk (LR) patients (n=48) with stage II/III colorectal cancer or gastric cancer (p=0.5545). It was respectively 92.3% and 84.3% for the HR patients (n=20) and LR patients (n=42) with stage II/III colorectal cancer (p=0.5073). Also, the rate was respectively 80% and 76.2% for the HR patients (n=7) and LR patients (n=26) with stage III colorectal cancer alone (p=0.9506). These results indicate that the 3Y-RFS rate is lower in ONC-positive patients with stage II/III colorectal cancer, suggesting that ONCs may have an influence on survival.

show abstract

“…Early diagnosis of this disease, the most lethal disease among gynecologic cancers, is difficult [1]. Molecular Markers are the most frequently searched topic in over the past decade in ovarian carcinom [2][3][4][5]. Nowadays, molecular markers which can show poor prognosis with high sensitivity and specificity are being investigated, but there are no markers that can stand out yet.…”

Section: Introductionmentioning

confidence: 99%

Epi̇telyal Over Kanserleri̇nde Cd24 Ve Cd44’ün İmmunohi̇stoki̇myasal Olarak Karşilaştirilmasi Ve Prognosti̇k Değeri̇

et al. 2020

View full text Add to dashboard Cite

Bu çalışmada epitelyal over kanserlerinden rezeke edilen tümör spesmenlerinde, CD 44 ve CD 24'ün ekpresyonları analiz edilerek, bu ekspresyon ve klinikopatolojik parametreler arasındaki ilişkiyi analiz edilmiştir. Gereç Ve Yöntemler: Bu çalışma, Kliniğimizin Jinekolojik Onkoloji Anabilim Dalı'nda tedavi edilen primer over kanseri olan 31 hastayı içermektedir. Bulgular: Anti-CD24 için incelenen 14 seröz karsinomlu spesmende; 6 örnekte şiddetli (+++) immünoreaktivite, 4 örnekte orta / şiddetli (++ / +++) immünoreaktivite, 2 numunede orta / şiddetli (++ / +++) immünoreaktivite, 2 örnekte hafif / orta (+ / + +) immünoreaktivite gözlendi. Bu 14 hasta CD 44 için incelendiğinde; 3 örnekte (++) modereta immünoreaktivitesi, 2 örnekte + / ++ (hafif / orta) immünoreaktivite, 9 örnekte + (hafif) immünoreaktivite gözlendi. Sonuç: CD44 immünoreaktivitesinin boyanma yoğunluğunun over epitelyal kanserlerinde sağkalım oranı ile ilişkili olduğu, ancak istatistiksel olarak anlamlı olmadığı tespit edildi. Her ne kadar CD 24 sağkalımı ile ilişkinin istatistiksel olarak anlamlı bulunmamasına rağmen, Over tümörlerde tanısal bir belirteç olarak kullanılabileceği düşünüldü.

show abstract

Clinical usefulness of serum and immunohistochemical markers in patients with stage Ia and Ic ovarian cancer

Cited by 7 publications

References 0 publications

Parameters of Blood Count and Tumor Markers in Patients with Borderline Ovarian Tumors: A Retrospective Analysis and Relation to Staging

Parameters of Blood Count and Tumor Markers in Patients with Borderline Ovarian Tumors: A Retrospective Analysis and Relation to Staging

Prospective study on the recurrence/metastasis of stage II/III colorectal cancer and gastric cancer associated with occult neoplastic cells in lymph node sinuses: Three-year interim results

Epi̇telyal Over Kanserleri̇nde Cd24 Ve Cd44’ün İmmunohi̇stoki̇myasal Olarak Karşilaştirilmasi Ve Prognosti̇k Değeri̇

Contact Info

Product

Resources

About